HF
APGE

HRT Financial’s Apogee Therapeutics APGE Stock Holding History

HRT Financial’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,211
Closed -$226K – 2828
2025
Q2 		$226K Buy
+5,211
New +$198K ﹤0.01% 2016
2024
Q3 		– Sell
-15,745
Closed -$619K – 2373
2024
Q2 		$619K Buy
+15,745
New +$764K ﹤0.01% 1201

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

HRT Financial's APGE Position: Q3 2025 in Review

HRT Financial sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 5,211 shares — an estimated $226K sold.

HRT Financial first reported a position in APGE in Q2 2024 and held it in 2 quarters. The position peaked at $619K in Q2 2024. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • HRT Financial reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 5,211 Apogee Therapeutics shares in Q3 2025, an estimated $226K.
  • HRT Financial first reported a position in Apogee Therapeutics in Q2 2024 and held it in 2 quarters.
  • HRT Financial's Apogee Therapeutics position peaked at $619K in Q2 2024.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.